CapsoVision (CV) vs Hyperfine (HYPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed Hyperfine (HYPR) over the past year, gaining 16.8% versus a loss of 48.0%. CapsoVision is the larger company by market cap ($327.6 million vs $58.0 million), about 5.7 times the size. CapsoVision converts more of its revenue into profit, with a net margin of -186.8% versus -262.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | HYPR |
|---|---|---|
| Share price | $6.11 | $0.5465 |
| Market cap | $327.56M | $57.96M |
| 1-day change | -3.17% | +4.27% |
| YTD return | -42.84% | -44.18% |
| 1-year return | +16.83% | -47.95% |
| 5-year return | — | -94.45% |
| EPS (TTM) | $-0.42 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $13.56M |
| Revenue growth (YoY) | +15.29% | +5.22% |
| Net income (latest FY) | $-25.32M | $-35.57M |
| Gross margin | 52.92% | 49.79% |
| Operating margin | -188.25% | -273.43% |
| Net margin | -186.77% | -262.29% |
| 52-week high | $15.37 | $1.94 |
| 52-week low | $4.50 | $0.488 |
| Distance from 52-week high | -60.25% | -71.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +55.48% | +271.45% |
| Average volume | 173.59K | 760.76K |
| Shares outstanding | 53.61M | 90.99M |
| Employees | 99 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CapsoVision is about 5.7 times larger than Hyperfine by market value ($327.56M vs $57.96M).
- CV has outperformed HYPR by 64.8 percentage points over the past year.
- CapsoVision is more profitable, keeping -186.8 cents of every revenue dollar as net income versus -262.3 cents for Hyperfine.
- CapsoVision grew revenue faster in its latest fiscal year (+15.29% vs +5.22%).
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
CV vs HYPR FAQ
Which is bigger, CapsoVision or Hyperfine?
CapsoVision (CV) is larger, with a market capitalization of $327.56M compared with $57.96M for Hyperfine (HYPR).
Which stock has performed better over the past year, CV or HYPR?
CV returned +16.83% over the past 12 months, compared with -47.95% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Hyperfine in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.